SNCA and Parkinson disease: In spite of the unresolved issues surrounding the analytical tests for PD biomarkers, our results suggest that the accurate measurement of α-synuclein levels in plasma, if combined with other biomarkers (i.e. analytes from the proteome, transcriptome, metabolome, as well as neuroimaging, etc), could potentially serve as a valuable tool for improving the diagnostic accuracy of PD.